somatotroph comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-05-09. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
Physicochemical behavior is dominated by the peptide backbone. The molecule is hydrophilic and carries a net positive charge near neutral pH, owing to several arginine and lysine residues. In solution it adopts a largely unstructured conformation, and aggregation is a known concern for peptide products of this size. Oxidation of methionine and deamidation of asparagine or glutamine residues are the principal chemical degradation routes. These liabilities shape how the material is formulated, handled, and analyzed, and they explain why lyophilized presentations are common in research settings.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
The peptide is synthesized chemically rather than extracted from biological sources. Solid-phase synthesis builds the chain from the C-terminus toward the N-terminus, after which the hexenoyl group is attached. Purity is typically assessed by high-performance liquid chromatography, and identity is confirmed by mass spectrometry. Regulatory review of the finished product focuses on these analytical controls, since small deviations in sequence or modification can change biological activity. Questions about long-term effects on the pituitary axis remain areas of continued investigation.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
=== Tools and databases === Tools developed at NBRC include the Dyslexia Assessment for Languages of India (DALI), a set of screening, assessment and remediation materials for dyslexia in Hindi, Kannada, Marathi and English, and BRAHMA, a set of brain templates for analysing structural and functional neuroimaging data from the Indian population. GAURI is a system that uses MRI data and neuropsychological tests for diagnosing Alzheimer's and Parkinson's diseases, and ANSH is a database of neuroimaging and neurochemical data from healthy older adults, people with mild cognitive impairment and people with Alzheimer's disease, intended for multi-site research. Other software described by NBRC researchers includes KALPANA, for processing magnetic resonance spectroscopy data; BHARAT, a big data framework for identifying early diagnostic markers of Alzheimer's disease; and PRATEEK, for integrating data from multiple neuroimaging methods.
Vehicle inspection is a procedure mandated by national or subnational governments in many countries, in which a vehicle is inspected to ensure that it conforms to regulations governing safety, emissions, or both. Inspection can be required at various times, e.g., periodically or on the transfer of title to a vehicle. If required periodically, it might be termed periodic motor vehicle inspection, or MOT test in the UK, or roadworthiness test in EU directives. Typical intervals are every two years (in EU) and every year (in UK). When a vehicle passes inspection, often a sticker is placed on the vehicle's windshield or registration plate to simplify later controls, but in some countries (such as Netherlands since 1994) this is no longer necessary. Vehicles are tested at inspection stations when due for inspection. Most US inspection decals/stickers display the month's number and the year. They are called testing centre in EU directives. Vehicle inspection exists in the United States. In Victoria, Australia, safety features checked include the structure of the vehicle, the tires (depth of tread), the wheels, the engine, steering, suspension, brakes, and lights and seatbelts.
Within the field of molecular biology, a protein-fragment complementation assay, or PCA, is a method for the identification and quantification of protein–protein interactions. In the PCA, the proteins of interest ("bait" and "prey") are each covalently linked to fragments of a third protein (e.g. DHFR, which acts as a "reporter"). Interaction between the bait and the prey proteins brings the fragments of the reporter protein in close proximity to allow them to form a functional reporter protein whose activity can be measured. This principle can be applied to many different reporter proteins and is also the basis for the yeast two-hybrid system, an archetypical PCA assay.
Experimental measurements of its density give values between 11.5 and 11.66 g/cm3: these are slightly lower than the theoretically expected value of 11.7 g/cm3 calculated from thorium's lattice parameters, perhaps due to microscopic voids forming in the metal when it is cast. These values lie between those of its neighbours actinium (10.1 g/cm3) and protactinium (15.4 g/cm3), part of a trend across the early actinides. Thorium can form alloys with many other metals. Addition of small proportions of thorium improves the mechanical strength of magnesium, and thorium–aluminium alloys have been considered as a way to store thorium in proposed future thorium nuclear reactors. Thorium forms eutectic mixtures with chromium and uranium, and it is completely miscible in both solid and liquid states with its lighter congener cerium.
Sources: en.wikipedia.org
== Resignation and arrest == On 24 April 2020, the Kosovo Specialist Chambers and Specialist Prosecutor's Office (KSC) located in The Hague filed a ten-count indictment for the court's consideration, charging Hashim Thaçi, Kadri Veseli and others for crimes against humanity and war crimes, including murder, enforced disappearance of persons, persecution, and torture. The indictment charged the suspects with approximately 100 murders of Kosovo Albanians, Serbs, Roma, and political opponents. According to the press release, the specialist prosecutor stated that it was necessary to make the issue public due to repeated efforts by Thaçi and Veseli to obstruct and undermine the Kosovo Specialist Chambers. Thaçi was then on a diplomatic visit to the United States, but returned to Kosovo on learning of the indictment. On 5 November 2020, Thaçi announced his resignation to reporters "to protect the integrity of the presidency of Kosovo". He was arrested the same day and transferred to The Hague. Thaçi was replaced by the speaker of the Assembly of Kosovo, Vjosa Osmani.
Platelet disorders (thrombocytopenic purpura) Primary thrombocytopenic purpura Secondary thrombocytopenic purpura Post-transfusion purpura Vascular disorders (nonthrombocytopenic purpura) Microvascular injury, as seen in senile (old age) purpura, when blood vessels are more easily damaged Hypertensive states Deficient vascular support Vasculitis, as in the case of Henoch–Schönlein purpura Coagulation disorders Disseminated intravascular coagulation (DIC) Scurvy (vitamin C deficiency) – defect in collagen synthesis due to lack of hydroxylation of procollagen results in weakened capillary walls and cells Meningococcemia Clumping fibrillary protein deposits caused by Amyloidosis Cocaine use with concomitant use of the one-time chemotherapy drug and now veterinary deworming agent levamisole can cause purpura of the ears, face, trunk, or extremities, sometimes needing reconstructive surgery. Levamisole is purportedly a common cutting agent. Decomposition of blood vessels including purpura is a symptom of acute radiation poisoning in excess of 2 Grays of radiation exposure. This is an uncommon cause in general, but is commonly seen in victims of nuclear disaster. Cases of psychogenic purpura are also described in the medical literature, some claimed to be due to "autoerythrocyte sensitization". Other studies suggest the local (cutaneous) activity of tissue plasminogen activator can be increased in psychogenic purpura, leading to substantial amounts of localized plasmin activity, rapid degradation of fibrin clots, and resultant bleeding.
Recent developments are focusing on novel primary ion species like C60+, ionized clusters of gold and bismuth, or large gas-cluster ion beams (e.g., Ar700+). The sensitive high-resolution ion microprobe (SHRIMP) is a large-diameter, double-focusing SIMS sector instrument based on the Liebl and Herzog design, and produced by Australian Scientific Instruments in Canberra, Australia.
In 1894, Hungarian inventor and industrialist István Röck started to manufacture a large industrial ammonia refrigerator which was powered by electric compressors (together with the Esslingen Machine Works). Its electric compressors were manufactured by the Ganz Works. At the 1896 Millennium Exhibition, Röck and the Esslingen Machine Works presented a 6-tonne capacity artificial ice producing plant. In 1906, the first large Hungarian cold store (with a capacity of 3,000 tonnes, the largest in Europe) opened in Tóth Kálmán Street, Budapest, the machine was manufactured by the Ganz Works. Until nationalisation after the Second World War, large-scale industrial refrigerator production in Hungary was in the hands of Röck and Ganz Works. Commercial refrigerator and freezer units, which go by many other names, were in use for almost 40 years prior to the common home models. They used gas systems such as ammonia (R-717) or sulfur dioxide (R-764), which occasionally leaked, making them unsafe for home use. Practical household refrigerators were introduced in 1915 and gained wider acceptance in the United States in the 1930s as prices fell and non-toxic, non-flammable synthetic refrigerants such as Freon-12 (R-12) were introduced. However, R-12 proved to be damaging to the ozone layer, causing governments to issue a ban on its use in new refrigerators and air-conditioning systems in 1994. The less harmful replacement for R-12, R-134a (tetrafluoroethane), has been in common use since 1990, but R-12 is still found in many old systems.
== Edwards Lecture Series == The Edwards Lecture Series is the longest-running lecture series at City, University of London, having reached its 44th edition in 2023. The lecture commemorates the work of physicist and Edwards Vacuum founder FD Edwards, a member of staff at City, University of London's predecessor institution, The Northampton Institute, and Past Master of the Worshipful Company of Scientific Instrument Makers. The lecture has a distinguished history and has been given by five Nobel Laureates over the years (Professor Denis Gabor, Professor Sir Harry Kroto, Professor Sir Peter Mansfield, Professor Sir Paul Nurse, and Professor Carlo Rubbia), as well as several Fellows of the Royal Society and Fellows of the Royal Academy of Engineering.
Sources: en.wikipedia.org
==== MeSH D13.695.667 – purine nucleotides ==== MeSH D13.695.667.138 – adenine nucleotides MeSH D13.695.667.138.124 – adenosine diphosphate MeSH D13.695.667.138.124.070 – adenosine diphosphate sugars MeSH D13.695.667.138.124.070.075 – adenosine diphosphate glucose MeSH D13.695.667.138.124.070.125 – adenosine diphosphate ribose MeSH D13.695.667.138.124.070.125.040 – o-acetyl-adp-ribose MeSH D13.695.667.138.124.070.125.195 – cyclic adp-ribose MeSH D13.695.667.138.180 – adenosine monophosphate MeSH D13.695.667.138.180.080 – adenosine phosphosulfate MeSH D13.695.667.138.236 – adenosine triphosphate MeSH D13.695.667.138.236.050 – adenylyl imidodiphosphate MeSH D13.695.667.138.236.250 – ethenoadenosine triphosphate MeSH D13.695.667.138.382 – coenzyme a MeSH D13.695.667.138.382.300 – acyl coenzyme a MeSH D13.695.667.138.382.300.020 – acetyl coenzyme a MeSH D13.695.667.138.382.300.500 – malonyl coenzyme a MeSH D13.695.667.138.382.300.700 – palmitoyl coenzyme a MeSH D13.695.667.138.395 – cyclic amp MeSH D13.695.667.138.395.225 – 8-bromo cyclic adenosine monophosphate MeSH D13.695.667.138.395.250 – bucladesine MeSH D13.695.667.138.410 – deoxyadenine nucleotides MeSH D13.695.667.138.506 – flavin-adenine dinucleotide MeSH D13.695.667.138.694 – nad MeSH D13.695.667.138.749 – nadp MeSH D13.695.667.138.850 – phosphoadenosine phosphosulfate MeSH D13.695.667.138.925 – vidarabine phosphate MeSH D13.695.667.454 – guanine nucleotides MeSH D13.695.667.454.160 – cyclic gmp MeSH D13.695.667.454.160.325 – dibutyryl cyclic gmp MeSH D13.695.667.454.200 – deoxyguanine nucleotides MeSH D13.695.667.454.340 – guanosine diphosphate MeSH D13.695.667.454.340.350 – guanosine diphosphate sugars MeSH D13.695.667.454.340.350.400 – guanosine diphosphate fucose MeSH D13.695.667.454.340.350.500 – guanosine diphosphate mannose MeSH D13.695.667.454.440 – guanosine pentaphosphate MeSH D13.695.667.454.480 – guanosine tetraphosphate MeSH D13.695.667.454.504 – guanosine triphosphate MeSH D13.695.667.454.504.380 – guanosine 5'-o-(3-thiotriphosphate) MeSH D13.695.667.454.504.400 – guanylyl imidodiphosphate MeSH D13.695.667.454.525 – 5'-guanylic acid MeSH D13.695.667.454.700 – rna caps MeSH D13.695.667.454.700.710 – rna cap analogs MeSH D13.695.667.616 – inosine nucleotides MeSH D13.695.667.616.300 – cyclic imp MeSH D13.695.667.616.400 – inosine diphosphate MeSH D13.695.667.616.500 – inosine monophosphate MeSH D13.695.667.616.800 – inosine triphosphate
=== CaMK2B === CaMK2B has an autophosphorylation site at Thr287. It functions as a targeting or docking module. Reverse transcription-polymerase chain reaction and sequencing analysis identified at least five alternative splicing variants of beta CaMKII (beta, beta6, betae, beta'e, and beta7) in brain and two of them (beta6 and beta7) were first detected in any species.
=== Pathology === As a bioactive lipid, ceramide has been implicated in a variety of physiological functions including apoptosis, cell growth arrest, differentiation, cell senescence, cell migration and adhesion. Roles for ceramide and its downstream metabolites have also been suggested in a number of pathological states including cancer, neurodegeneration, diabetes, microbial pathogenesis, obesity, and inflammation. Several distinct ceramides potently predict major adverse cardiovascular events (MACE), namely C16:0, C18:0, and C24:1, although C24:0 has an inverse relationship. C16-C18 are harmful in the liver. Ceramide levels are positively correlated with inflammation and oxidative stress in the liver, and the onset and progression of non-alcoholic fatty liver disease (NAFLD) is associated with elevated ceramide in hepatocytes. Dietary intake of saturated fat has been shown to increase serum ceramide and increase insulin resistance. Although initial studies showed increased insulin resistance in muscle, subsequent studies also showed increased insulin resistance in liver and adipose tissue. Interventions that limit ceramide synthesis or increase ceramide degradation lead to improved health (reduced insulin resistance and reduced fatty liver disease, for example). Ceramides induce skeletal muscle insulin resistance when synthesized as a result of saturated fat activation of TLR4 receptors. Unsaturated fat does not have this effect. Ceramides induce insulin resistance in many tissues by inhibition of Akt/PKB signaling.
In 1957, this total fell to five when one of the Liberal MPs died and the subsequent by-election was lost to the Labour Party, which selected the former Liberal Deputy Leader Megan Lloyd George as its own candidate. The Liberal Party seemed close to extinction. During this low period, it was often joked that Liberal MPs could hold meetings in the back of one taxi.
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.